Eptifibatide is indicated for:

• Patients with acute coronary syndrome (unstable angina or non–ST-segment elevation myocardial infarction), including those receiving medical management as well as those undergoing percutaneous coronary intervention (PCI).
• Patients undergoing PCI procedures, including individuals receiving intracoronary stent placement.

Eptifibatide is a glycoprotein IIb/IIIa inhibitor that works by blocking platelet aggregation. It prevents fibrinogen binding to platelets, thereby reducing thrombus formation. This action is particularly beneficial in patients with acute coronary syndrome and those undergoing PCI, as it helps maintain blood flow and reduces the risk of clot-related complications.

Acute Coronary Syndrome-

• In patients with normal renal function: The recommended adult dosage of Eptifibatide is an IV bolus of 180 µg/kg as soon as possible following diagnosis, followed by a continuous infusion of 2 µg/kg/min until hospital discharge or initiation of CABG surgery, up to 72 hours. If a patient is to undergo a PCI while receiving Eptifibatide, the infusion should be continued up to hospital discharge, or for up to 18 to 24 hours after the procedure, whichever comes first, allowing for up to 96 hours of therapy.
• In patients with creatinine clearance <50 ml/min: The recommended adult dosage of Eptifibatide is an IV bolus of 180 µg/kg as soon as possible following diagnosis, immediately followed by a continuous infusion of 1 µg/kg/min.

Percutaneous Coronary Intervention (PCI)-

•  In patients with normal renal function: The recommended adult dosage of Eptifibatide is IV bolus of 180 µg/kg administered immediately before the initiation of PCI followed by a continuous infusion of 2 µg/kg/min and a second 180 µg/kg bolus 10 minutes after the first bolus. Infusion should be continued until hospital discharge, or for up to 18 to 24 hours, whichever comes first. A minimum of 12 hours of infusion is recommended.
• In patients with creatinine clearance <50 ml/min: The recommended adult dose of Eptifibatide is an IV bolus of 180 µg/kg administered immediately before the initiation of the procedure, immediately followed by a continuous infusion of 1 µg/kg/min and a second 180 µg/kg bolus administered 10 minutes after the first. In patients who undergo CABG surgery, Eptifibatide infusion should be discontinued prior to surgery.

Aspirin and Heparin Dosing Recommendations: In the clinical trials that showed Eptifibatide to be effective, most patients received concomitant aspirin and heparin. The recommended aspirin and heparin doses to be used are as follows:

Acute Coronary Syndrome-
Aspirin: 160 to 325 mg orally initially and daily thereafter.

Heparin: Target aPTT 50 to 70 seconds during medical management

• If weight >70 kg, 5000 U bolus followed by infusion of 1000 U/hr.
• If weight <70 kg, 60 U/kg bolus followed by infusion of 12 U/kg/hr.

Target ACT 200 to 300 seconds during PCI

• If heparin is initiated prior to PCI, additional boluses during PCI to maintain an ACT target of 200 to 300 seconds.
• Heparin infusion after the PCI is discouraged.

PCI-
Aspirin: 160 to 325 mg orally 1 to 24 hours prior to PCI and daily thereafter.

Heparin: Target ACT 200 to 300 seconds

• 60 U/kg bolus initially in patients not treated with heparin within 6 hours prior to PCI.
• Additional boluses during PCI to maintain ACT within target.
• Heparin infusion after the PCI is strongly discouraged.

Patients requiring thrombolytic therapy should have Eptifibatide infusions stopped

In clinical studies, Eptifibatide has been administered alongside unfractionated heparin and aspirin. In certain dual, placebo-controlled trials involving routine coronary stenting, dipyridamole was also used. Due to its inhibitory effect on platelet aggregation, caution is required when Eptifibatide is combined with other drugs that influence hemostasis, such as thrombolytics, oral anticoagulants, NSAIDs, or dipyridamole, to reduce the risk of bleeding. Concomitant use with other glycoprotein IIb/IIIa inhibitors should be avoided. Enoxaparin does not significantly alter the pharmacokinetics of Eptifibatide.

• History of bleeding disorders or clinically significant bleeding within the past 30 days.
• Severe uncontrolled hypertension (systolic blood pressure >200 mmHg or diastolic blood pressure >110 mmHg).
• Recent major surgical procedures or trauma.
• History of stroke within the last 30 days or any history of hemorrhagic stroke.
• Current or recent use of another parenteral GP IIb/IIIa inhibitor.
• Severe hepatic impairment.
• Known hypersensitivity to any component of the formulation.

Bleeding is the most frequently observed adverse effect. Other reported side effects include intracranial hemorrhage, stroke, thrombocytopenia, allergic reactions, and hypotension.

Animal studies have not demonstrated harmful effects on the fetus with Eptifibatide. However, adequate and well-controlled studies in pregnant women are lacking. It is not known whether Eptifibatide is excreted in human breast milk. Since many drugs are excreted in breast milk, caution is advised when administering Eptifibatide to breastfeeding mothers.

In patients undergoing PCI, Eptifibatide injection is linked to an increased risk of both major and minor bleeding at the arterial access site. Appropriate precautions should be taken to reduce bleeding risk in these patients.

If bleeding cannot be controlled by applying pressure, Eptifibatide infusion along with concurrent heparin should be discontinued immediately.

As Eptifibatide inhibits platelet aggregation, it should be used cautiously with medications that affect hemostasis, including thrombolytics, oral anticoagulants, NSAIDs, and dipyridamole.

Concomitant use with other GP IIb/IIIa inhibitors is not recommended.

Eptifibatide is partially eliminated by the kidneys, and plasma levels may increase in patients with renal impairment (creatinine clearance <50 ml/min). Therefore, the infusion dose should be reduced to 1 mcg/kg/min in such patients. It is contraindicated in patients requiring dialysis.

Caution is advised when administering Eptifibatide to patients with a platelet count below 100,000/mm³.

Bleeding is the most frequently observed complication during Eptifibatide therapy. Most major bleeding events occur at the femoral artery access site. Oropharyngeal, genitourinary, gastrointestinal, and retroperitoneal bleeding may also occur more frequently compared to placebo.

Procedures such as arterial or venous punctures, intramuscular injections, and the use of urinary catheters, nasotracheal tubes, or nasogastric tubes should be minimized. When establishing intravenous access, noncompressible sites (such as subclavian or jugular veins) should be avoided.

Before initiating Eptifibatide therapy, baseline laboratory tests should be performed to detect any existing hemostatic abnormalities, including hematocrit or hemoglobin, platelet count, serum creatinine, and PT/aPTT. In patients undergoing PCI, activated clotting time (ACT) should also be monitored.

Use in Children: Safety and effectiveness of Eptifibatide in pediatric patients have not been established.

Limited information is available regarding overdose. Reported symptoms include loss of righting reflex, decreased muscle tone, and petechial hemorrhages in animal studies. Eptifibatide is not extensively protein-bound and may be partially removed by dialysis.

Antiplatelet agent.

Store refrigerated at 2–8°C. Vials may be kept at room temperature for a limited period if necessary. Protect from light and discard any unused portion.